SUPN - Supernus Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Supernus Pharmaceuticals, Inc.

1550 East Gude Drive
Rockville, MD 20850
United States
301-838-2500
http://www.supernus.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees448

Key Executives

NameTitlePayExercisedYear Born
Mr. Jack A. KhattarFounder, Pres, CEO, Sec. & Director1.42MN/A1961
Mr. Gregory S. PatrickSr. VP & CFO539.35k4.37M1951
Dr. Padmanabh P. BhattChief Scientific Officer & Sr. VP of Intellectual Property533.53k5.08M1957
Dr. Stefan K. F. SchwabeChief Medical Officer and Exec. VP of R&D582.88k2.74M1952
Dr. Todd Horich M.B.A., Ph.D.VP of MarketingN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company's product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy. The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.

Corporate Governance

Supernus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 3; Board: 5; Shareholder Rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.